No abstract

Background: Background:Anemia is a common complication of chronic inflammation. It is caused by an increased production of the ironregulatory hormone hepcidin, that leads to iron restriction, and by decreased erythrocytes sensitivity to erythropoietin (EPO) stimulation. Anemia of Chronic Kidney Disease (CKD) is a form of anemia of inflammation, in which progressive renal damage, besides causing systemic inflammation and iron deficiency, impairs erythropoietin (EPO) production. Current EPO-based treatments may cause off-target effects on long term and often require iron supplementation, mainly for CKD.Transferrin Receptor 2 (TFR2) modulates iron homeostasis in the liver, contributing to the transcriptional activation of hepcidin, and acts as a brake of EPO signaling in erythroid cells. Its selective deletion in the bone marrow (BM, Tfr2 BMKO ) enhances erythropoiesis both in wild-type and thalassemic mice.